‘Extremely dangerous heat' hits US, NWS issues magenta, red alerts as mercury crosses 100°F
United States is reeling under 'extremely dangerous heat' impacting nearly 160 million people. With mercury soaring and temperatures touching three digits, advisories have been issued in several cities to take measure to protect oneself from 'life-threatening' heatwave.
Health warnings were issued as US' first significant heatwave set off over the weekend, reaching dangerously high temperatures in Washington DC, Baltimore, Philadelphia, New York City and Boston. As mercury soared and high humidity levels added to the heat, the heat index touched 110°F/43 degree Celsius on East Coast.
Urging citizens to stay hydrated, take shelter in cooling centres or public libraries with air conditioning, wear light clothing and seek medical assistance in case of heatstroke, the health advisories warned about risks to life from heat exhaustion.
'An upper-level high over the Ohio Valley will be quasi-stationary through Wednesday and contribute to Extreme Heat Warnings and Heat Advisories across much of the eastern third of the country, affecting nearly 160 million people,' the National Weather Service (NWS) said in its press release dated June 24.
It further warned that about high heat levels at night and stated, 'Light winds, sunny days, record-high daytime, and high overnight temperatures will create a lack of overnight cooling, significantly increasing the danger.'
Warning against Heat-related illnesses, NWS said, 'This heat level can be dangerous to anyone without effective cooling and/or adequate hydration, especially those engaging in lengthy outdoor activities.' Amid orange, red and magenta alerts, the weather agency advised residents to 'Wear lightweight and loose-fitting clothing. Take action when you see symptoms of heat exhaustion and heat stroke.'
"There is a disconnect between the severity of heat waves as a public health risk and the public recognition of that risk," Reuters quoted Howard Frumkin, an expert in environmental and occupational health sciences at the University of Washington, as saying. Amid expected spike in US electricity demand, electrical grid operators directed power plants to be ready to run at maximum force.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
an hour ago
- First Post
Rights advocates urge suspension of US-backed aid group in Gaza over alleged law violations
Gaza Humanitarian Foundation has been associated with the deaths of several Palestinians who have been shot dead in the past couple of weeks as they rushed to aid distribution centres run by the group read more Palestinians gather to receive food cooked by a charity kitchen, amid a hunger crisis, as the Israel-Gaza conflict continues, in Khan Younis in the southern Gaza Strip, December 4, 2024. File image/Reuters As many as 15 rights groups have warned the US-backed Gaza Humanitarian Foundation (GHF) that they might face legal challenges over international law violations and have called on it and other private organisations to cease their operations in the region. In a letter addressed to GHF and the affiliated Safe Reach Solutions and UG Solutions, the rights groups wrote that the 'private contractors' working to feed Gazans in collaboration with the Israeli government risk 'aiding and abetting or otherwise being complicit in crimes under international law, including war crimes, crimes against humanity, or genocide'. STORY CONTINUES BELOW THIS AD GHF has been associated with the deaths of several Palestinians who have been shot dead in the past couple of weeks as they rushed to aid distribution centres run by the group. The group replaced UN-run relief operations in Gaza after they were banned from the region. 'GHF's militarized model, coupled with its close collaboration with Israeli authorities, undermines the core humanitarian principles of humanity, neutrality, impartiality, and independence," the letter added. Last week, US Senator Elizabeth Warren raised concerns over the Trump administration's proposal to redirect $500 million from USAID, an agency that has already seen significant cuts under the administration, to the Global Health Foundation (GHF), which is registered in both the United States and Switzerland. 'The questions surrounding GHF – its funding sources and connection to the Trump Administration, its use of private contractors, its ability to serve and be seen as a neutral entity, its abandonment by its founders, and its basic competence in providing aid – must be answered before the State Department commits any funding to the organization,' Warren wrote. On Tuesday, Gaza's civil defence agency said Israeli forces killed 21 people waiting for aid near a distribution site in the centre of the Palestinian territory. Civil defence spokesman Mahmud Bassal told AFP that 21 people were killed and around 150 wounded 'as a result of the Israeli occupation forces' targeting of gatherings of citizens waiting for aid… in the central Gaza Strip with bullets and tank shells' in the early hours of Tuesday. STORY CONTINUES BELOW THIS AD With inputs from agencies
India Today
2 hours ago
- India Today
Wegovy, widely popular weight-loss drug, launched in India: Price, dosage
Wegovy is a once-weekly GLP1 receptor agonist approved in India for the treatment of obesity. (Photo: Reuters) Novo Nordisk introduces Wegovy for chronic weight management in India Wegovy contains semaglutide, a weekly injectable GLP-1 receptor agonist Wegovy comes after its rival drug Mounjaro was launched in March Danish pharmaceutical giant Novo Nordisk has officially launched its flagship obesity drug Wegovy (semaglutide) in India, announced Managing Director Vikrant Shrotriya on Tuesday. Wegovy is a once-weekly GLP1 receptor agonist (separate from Ozempic), approved in India for the treatment of chronic weight management in adults who are obese or overweight with at least one weight-related health condition. Wegovy is a once-weekly injection that contains semaglutide as its main ingredient, the same compound used in Novo Nordisk's blockbuster diabetes drug, Ozempic. A lower-dose version of semaglutide has already been available in India since 2022 under the brand name Rybelsus, which comes in the form of a pill and is used to treat type 2 diabetes. The price for the 0.25 mg, 0.5 mg, and 1 mg doses of Wegovy is Rs 17,345 per month, which comes to a weekly cost of approximately Rs 4,366. The 1.7 mg dose is priced at Rs 24,280 per month, while the 2.4 mg dose, the highest, costs Rs 26,015 for a month's supply. Semaglutide works by copying the action of a natural hormone in the gut called GLP-1. This hormone sends signals to the brain that you're full, helping you eat less and regulate blood sugar. People using this drug have been shown to lose about 15% of their body weight over a little more than a year (68 weeks). The launch of Wegovy in India comes just before its patent for semaglutide expires next year. After that, several Indian pharmaceutical companies are expected to introduce cheaper generic versions, which could make the drug more affordable for many. Obesity is now recognised as a major cause of serious health problems, including diabetes, heart disease, kidney and liver disorders, and even some types of cancer. Originally set for a 2026 release, Novo Nordisk advanced Wegovy's Indian debut to 2025 in response to intense competition, especially from Eli Lilly's Mounjaro (tirzepatide), which entered the market in March 2025. Both Wegovy and its rival drug Mounjaro (anti-obesity drug by Eli Lilly) are meant for people with a Body Mass Index (BMI) of obver 30. Danish pharmaceutical giant Novo Nordisk has officially launched its flagship obesity drug Wegovy (semaglutide) in India, announced Managing Director Vikrant Shrotriya on Tuesday. Wegovy is a once-weekly GLP1 receptor agonist (separate from Ozempic), approved in India for the treatment of chronic weight management in adults who are obese or overweight with at least one weight-related health condition. Wegovy is a once-weekly injection that contains semaglutide as its main ingredient, the same compound used in Novo Nordisk's blockbuster diabetes drug, Ozempic. A lower-dose version of semaglutide has already been available in India since 2022 under the brand name Rybelsus, which comes in the form of a pill and is used to treat type 2 diabetes. The price for the 0.25 mg, 0.5 mg, and 1 mg doses of Wegovy is Rs 17,345 per month, which comes to a weekly cost of approximately Rs 4,366. The 1.7 mg dose is priced at Rs 24,280 per month, while the 2.4 mg dose, the highest, costs Rs 26,015 for a month's supply. Semaglutide works by copying the action of a natural hormone in the gut called GLP-1. This hormone sends signals to the brain that you're full, helping you eat less and regulate blood sugar. People using this drug have been shown to lose about 15% of their body weight over a little more than a year (68 weeks). The launch of Wegovy in India comes just before its patent for semaglutide expires next year. After that, several Indian pharmaceutical companies are expected to introduce cheaper generic versions, which could make the drug more affordable for many. Obesity is now recognised as a major cause of serious health problems, including diabetes, heart disease, kidney and liver disorders, and even some types of cancer. Originally set for a 2026 release, Novo Nordisk advanced Wegovy's Indian debut to 2025 in response to intense competition, especially from Eli Lilly's Mounjaro (tirzepatide), which entered the market in March 2025. Both Wegovy and its rival drug Mounjaro (anti-obesity drug by Eli Lilly) are meant for people with a Body Mass Index (BMI) of obver 30. Join our WhatsApp Channel
India Today
3 hours ago
- India Today
Asia heating up twice as fast: Climate change report cites recent events
With the world already struggling to find ways to effectively address climate change, a new report on the global crisis has sounded concerns, especially for Asian, with fresh water sources and coastal areas seriously World Meteorological Organization's (WMO) "State of the Climate in Asia 2024" report has highlighted alarming climate changes across Asia recently, saying the continent has heated up twice as fast as the rest of the report reveals that the continent is facing unprecedented environmental challenges, saying in 2024, Asia experienced one of the warmest years on record. With average temperatures averaging 1.04 degrees Celsius above the 1991-2020 baseline, the continent is warming nearly twice as fast as the global average, the report rapid temperature rise has accelerated glacier melting in key mountain ranges, including the Himalayas and the Tian Shan mountain range in Central Asia, threatening vital freshwater sources and SURFACE TEMPERATURE RISE RISKS COASTAL AREASAccording to the State of the Climate in Asia 2024 report, sea-surface temperatures in the region have also soared to record highs. Due to the record-high temperatures, sea levels along Asia's Pacific and Indian Ocean coastlines rose faster than the global average. These trends have heightened the vulnerability of millions living in coastal areas of the continent, including are increasing risks from flooding and storm surges. The continent also saw a sharp increase in extreme weather events throughout BRACES FOR DEADLY HEATWAVEadvertisementThe report further claimed that prolonged heat waves struck parts of Asia, causing hundreds of heat-related deaths, particularly in India and Japan. Marine heatwaves expanded dramatically, reaching a record 15 million square kilometers, severely impacting marine biodiversity. Tropical Cyclone Yagi emerged as the strongest storm of the year, inflicting widespread damage across Southeast Asia. Yagi left dozens dead in northern Vietnam last Central Asia faced its worst floods in over 70 years, while the United Arab Emirates (UAE) experienced unprecedented rainfall, severely disrupting infrastructure. Nepal endured devastating floods in September 2024, resulting in at least 246 fatalities. However, timely early warning systems and coordinated response efforts helped save thousands of FOR URGENT CLIMATE STRATEGIESThe report underlines the urgent need for robust climate adaptation strategies. It emphasises the critical role of national meteorological services in improving disaster preparedness to protect lives and livelihoods in an era of escalating climate Asia's climate continues to warm rapidly, proactive measures are essential to mitigate the human and economic toll of these extreme environmental changes, it added.- EndsMust Watch
